Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033959 | 0.98 | CHRM1 (0.54) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL21802537 | 0.92 | SIGMAR1 (0.53) | CHRM1HRH2SLC6A9 | |
| SCHEMBL4030458 | 0.91 | HRH2 (0.54) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL15055273 | 0.90 | CHRM1 (0.54) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL15055274 | 0.90 | CHRM1 (0.54) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL21763640 | 0.88 | CHRM1 (0.53) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL10566689 | 0.87 | CHRM1 (0.52) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL26814710 | 0.86 | CHRM1 (0.60) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL14930106 | 0.86 | CHRM1 (0.51) | CHRM1MAPTPDK1PDK2PDK3 | |
| SCHEMBL20305037 | 0.84 | L3MBTL1 (0.51) | MAPTALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013095275-A1 | NOVEL HEPATITIS C VIRUS INHIBITORS | MEDIVIR AB (SE) | 2013-06-27 | — | — | WO | disclosed |
| US-8367674-B2 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100120786-A1 | Piperazine Derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090270336-A1 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009128947-A1 | PIPERAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270336-A1 | Piperazine derivatives | CCR5, CCR2, CXCR3 | CHRM1 2938/4885MAPT 3818/4885PDK1 1936/4885 |
| US-20100120786-A1 | Piperazine Derivatives | CCR5, CCR2, CXCR3 | CHRM1 2938/4885MAPT 3818/4885PDK1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.